Sichuan Friendly Pharma Receives FDA Warning Letter
“To our knowledge, this represents one of the very few cases for a US IND approval for which a Chinese company completed the whole process,” said Dr. Ting Xu, chairman and CEO of Alphamab. “We are thrilled by the milestone achievement. With KN035 as a building block for bi-specifics, Alphamab has also initiated the development of next-generation immuno-oncology therapeutics.”